{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:35:09Z","timestamp":1777336509038,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Science and Technology Innovation Action Plan","award":["NO.23YF1448400"],"award-info":[{"award-number":["NO.23YF1448400"]}]},{"name":"Shanghai Science and Technology Innovation Action Plan","award":["NO.23Y31920203"],"award-info":[{"award-number":["NO.23Y31920203"]}]},{"name":"Shanghai \u201cRising Stars of Medical Talents\u201d Youth Development Program","award":["NO.RY411.19.01.14"],"award-info":[{"award-number":["NO.RY411.19.01.14"]}]},{"name":"Shanghai Municipal Health Commission Health Industry Clinical Research Special Project","award":["NO.20244Y0026"],"award-info":[{"award-number":["NO.20244Y0026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12012-026-10115-w","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:45:29Z","timestamp":1776048329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Real-World Disproportionality Analysis of Drug-Induced Heart Failure: Integrating FAERS Database and AHA Statement"],"prefix":"10.1007","volume":"26","author":[{"given":"Da","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yidan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"10115_CR1","doi-asserted-by":"publisher","unstructured":"Bozkurt, B., Coats, A. J. S., Tsutsui, H. (2021). Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. European Journal of Heart Failure, 23(3): 352\u2013380. https:\/\/doi.org\/10.1002\/ejhf.2115","DOI":"10.1002\/ejhf.2115"},{"issue":"9","key":"10115_CR2","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani, S. S., Alonso, A., Benjamin, E. J., et al. (2020). Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation, 141(9), e139\u2013e596. https:\/\/doi.org\/10.1161\/CIR.0000000000000757","journal-title":"Circulation"},{"issue":"10159","key":"10115_CR3","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the global burden of disease study 2017. Lancet, 392(10159), 1789\u20131858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7","journal-title":"Lancet"},{"issue":"8","key":"10115_CR4","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao, C. W., Aday, A. W., Almarzooq, Z. I., et al. (2023). Heart disease and stroke statistics-2023 update: A report from the American heart association. Circulation, 147(8), e93\u2013e621. https:\/\/doi.org\/10.1161\/CIR.0000000000001123","journal-title":"Circulation"},{"issue":"18","key":"10115_CR5","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18), e876\u2013e894. https:\/\/doi.org\/10.1161\/CIR.0000000000001062","journal-title":"Circulation"},{"issue":"10","key":"10115_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","volume":"21","author":"MS Khan","year":"2024","unstructured":"Khan, M. S., Shahid, I., Bennis, A., et al. (2024). Global epidemiology of heart failure. Nature Reviews Cardiology, 21(10), 717\u2013734. https:\/\/doi.org\/10.1038\/s41569-024-01046-6","journal-title":"Nature Reviews Cardiology"},{"issue":"2","key":"10115_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.therap.2023.10.008","volume":"79","author":"A Destere","year":"2024","unstructured":"Destere, A., Merino, D., Lavrut, T., et al. (2024). Drug-induced cardiac toxicity and adverse drug reactions, a narrative review. Therapie, 79(2), 161\u2013172. https:\/\/doi.org\/10.1016\/j.therap.2023.10.008","journal-title":"Therapie"},{"issue":"1","key":"10115_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","volume":"6","author":"M Arrigo","year":"2020","unstructured":"Arrigo, M., Jessup, M., Mullens, W., et al. (2020). Acute heart failure. Nature Reviews Disease Primers, 6(1), 16. https:\/\/doi.org\/10.1038\/s41572-020-0151-7","journal-title":"Nature Reviews Disease Primers"},{"issue":"6","key":"10115_CR9","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","volume":"134","author":"RL Page","year":"2016","unstructured":"Page, R. L., O\u2019Bryant, C. L., Cheng, D., et al. (2016). Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation, 134(6), e32\u201369. https:\/\/doi.org\/10.1161\/CIR.0000000000000426","journal-title":"Circulation"},{"key":"10115_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar, M., Tawfiq, A. M., Hassan, N., et al. (2020). Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: Current status, challenges and the future. Therapeutic Advances in Drug Safety, 11, 1\u201311. https:\/\/doi.org\/10.1177\/2042098620938595","journal-title":"Therapeutic Advances in Drug Safety"},{"issue":"1","key":"10115_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","volume":"20","author":"BM Bonora","year":"2021","unstructured":"Bonora, B. M., Raschi, E., Avogaro, A., et al. (2021). SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovascular Diabetology, 20(1), 39. https:\/\/doi.org\/10.1186\/s12933-021-01243-4","journal-title":"Cardiovascular Diabetology"},{"issue":"3","key":"10115_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/cpt.3139","volume":"115","author":"D Li","year":"2024","unstructured":"Li, D., Wang, H., Qin, C., et al. (2024). Drug-induced acute pancreatitis: a real-world pharmacovigilance study using the FDA adverse event reporting system database. Clinical Pharmacology & Therapeutics, 115(3), 535\u2013544. https:\/\/doi.org\/10.1002\/cpt.3139","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10115_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y., Zhou, L., Shen, Y., et al. (2024). Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. Journal of Affective Disorders, 346, 223\u2013229. https:\/\/doi.org\/10.1016\/j.jad.2023.11.025","journal-title":"Journal of Affective Disorders"},{"issue":"8","key":"10115_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S., & Sacks, S. T. (2004). The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiology and Drug Safety, 13(8), 519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"6","key":"10115_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans, S. J. W., Waller, P. C., & Davis, S. (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety, 10(6), 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"4","key":"10115_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A., Lindquist, M., Edwards, I. R., et al. (1998). A Bayesian neural network method for adverse drug reaction signal generation. European Journal of Clinical Pharmacology, 54(4), 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10115_CR17","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730070-00011","author":"A Bate","year":"2007","unstructured":"Bate, A. (2007). Bayesian Confidence Propagation Neural Network. Drug Safety, 30(7): 623\u2013625. https:\/\/doi.org\/10.2165\/00002018-200730070-00011."},{"key":"10115_CR18","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 47(Supplement 1): S158-S178. https:\/\/doi.org\/10.2337\/dc24-S009","DOI":"10.2337\/dc24-S009"},{"issue":"1","key":"10115_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","volume":"10","author":"A Mocumbi","year":"2024","unstructured":"Mocumbi, A., Humbert, M., Saxena, A., et al. (2024). Pulmonary hypertension. Nature Reviews Disease Primers, 10(1), 1. https:\/\/doi.org\/10.1038\/s41572-023-00486-7","journal-title":"Nature Reviews Disease Primers"},{"issue":"4","key":"10115_CR20","doi-asserted-by":"publisher","first-page":"ITC49","DOI":"10.7326\/AITC202104200","volume":"174","author":"D Poch","year":"2021","unstructured":"Poch, D., & Mandel, J. (2021). Pulmonary hypertension. Annals of Internal Medicine, 174(4), ITC49\u2013ITC64. https:\/\/doi.org\/10.7326\/AITC202104200","journal-title":"Annals of Internal Medicine"},{"issue":"17","key":"10115_CR21","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese, G., Becher, P. M., Lund, L. H., et al. (2023). Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovascular Research, 118(17), 3272\u20133287. https:\/\/doi.org\/10.1093\/cvr\/cvac013","journal-title":"Cardiovascular Research"},{"issue":"9982","key":"10115_CR22","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402","volume":"385","author":"RE Gilbert","year":"2015","unstructured":"Gilbert, R. E., & Krum, H. (2015). Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy. Lancet, 385(9982), 2107\u20132117. https:\/\/doi.org\/10.1016\/S0140-6736(14)61402","journal-title":"Lancet"},{"issue":"7","key":"10115_CR23","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3390\/biomedicines12071572","volume":"12","author":"X Li","year":"2024","unstructured":"Li, X., Zhou, X., & Gao, L. (2024). Diabetes and heart failure: A literature review, reflection and outlook. Biomedicines, 12(7), 1572. https:\/\/doi.org\/10.3390\/biomedicines12071572","journal-title":"Biomedicines"},{"key":"10115_CR24","doi-asserted-by":"publisher","unstructured":"Sharma, G., Chaurasia, S. S., Carlson, M. A. (2024). Recent advances associated with cardiometabolic remodeling in diabetes-induced heart failure. The American Journal of Physiology-Heart and Circulatory Physiology, 327(6):H1327-H1342. https:\/\/doi.org\/10.1152\/ajpheart.00539","DOI":"10.1152\/ajpheart.00539"},{"issue":"1","key":"10115_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12933-024-02436-3","volume":"23","author":"P Valensi","year":"2024","unstructured":"Valensi, P. (2024). Evidence of a bi-directional relationship between heart failure and diabetes: A strategy for the detection of glucose abnormalities and diabetes prevention in patients with heart failure. Cardiovascular Diabetology, 23(1), 354. https:\/\/doi.org\/10.1186\/s12933-024-02436-3","journal-title":"Cardiovascular Diabetology"},{"issue":"5","key":"10115_CR26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovi\u0107","year":"2018","unstructured":"Seferovi\u0107, P. M., Petrie, M. C., Filippatos, G. S., et al. (2018). Type 2 diabetes mellitus and heart failure: A position statement from the heart failure association of the european society of cardiology. European journal of heart failure, 20(5), 853\u2013872. https:\/\/doi.org\/10.1002\/ejhf.1170","journal-title":"European journal of heart failure"},{"issue":"14","key":"10115_CR27","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica, B. M., Bhatt, D. L., Braunwald, E., et al. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine, 369(14), 1317\u20131326. https:\/\/doi.org\/10.1056\/NEJMoa1307684","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10115_CR28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1161\/CIRCRESAHA.121.318670","volume":"128","author":"H Taegtmeyer","year":"2021","unstructured":"Taegtmeyer, H. (2021). Heart failure in diabetes still a vexing problem. Circulation Research, 128(3), 358\u2013359. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318670","journal-title":"Circulation Research"},{"issue":"2","key":"10115_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cardfail.2023.09.005","volume":"30","author":"AS Bhatt","year":"2024","unstructured":"Bhatt, A. S., Fonarow, G. C., Greene, S. J., et al. (2024). Medical therapy before, during and after hospitalization in medicare beneficiaries with heart failure and diabetes: Get with the guidelines \u2013 heart failure registry. Journal of Cardiac Failure, 30(2), 319\u2013328. https:\/\/doi.org\/10.1016\/j.cardfail.2023.09.005","journal-title":"Journal of Cardiac Failure"},{"issue":"36","key":"10115_CR30","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A., Metra, M., Adamo, M., et al. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(36), 3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"European Heart Journal"},{"issue":"10","key":"10115_CR31","doi-asserted-by":"publisher","first-page":"e2441765","DOI":"10.1001\/jamanetworkopen.2024.41765","volume":"7","author":"HY Su","year":"2024","unstructured":"Su, H. Y., Yang, C. Y., Lee, Y. H., et al. (2024). Cardiovascular risks with SGLT2 inhibitors in clinical practice among patients with type 2 diabetes. JAMA Network Open, 7(10), e2441765. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.41765","journal-title":"JAMA Network Open"},{"issue":"1","key":"10115_CR32","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12933-024-02415-8","volume":"23","author":"A Albulushi","year":"2024","unstructured":"Albulushi, A., Tanoh, D. B., Almustafa, A., et al. (2024). Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: A meta-analysis. Cardiovascular Diabetology, 23(1), 324. https:\/\/doi.org\/10.1186\/s12933-024-02415-8","journal-title":"Cardiovascular Diabetology"},{"issue":"2","key":"10115_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.hfc.2019.08.004","volume":"40","author":"AM Marra","year":"2022","unstructured":"Marra, A. M., Benjamin, N., Cittadini, A., et al. (2022). When pulmonary hypertension complicates heart failure. Cardiology Clinics, 40(2), 191\u2013198. https:\/\/doi.org\/10.1016\/j.hfc.2019.08.004","journal-title":"Cardiology Clinics"},{"issue":"35","key":"10115_CR34","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1093\/eurheartj\/ehae467","volume":"45","author":"C Fauvel","year":"2024","unstructured":"Fauvel, C., Damy, T., Berthelot, E., et al. (2024). Post-capillary pulmonary hypertension in heart failure: Impact of current definition in the PH-HF multicentre study. European Heart Journal, 45(35), 3274\u20133288. https:\/\/doi.org\/10.1093\/eurheartj\/ehae467","journal-title":"European Heart Journal"},{"issue":"9","key":"10115_CR35","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-2600(23)00264-3","volume":"11","author":"M Humbert","year":"2023","unstructured":"Humbert, M., Sitbon, O., Guignabert, C., et al. (2023). Treatment of pulmonary arterial hypertension: recent progress and a look to the future. Lancet Respiratory Medicine, 11(9), 804\u2013819. https:\/\/doi.org\/10.1016\/S2213-2600(23)00264-3","journal-title":"Lancet Respiratory Medicine"},{"issue":"16","key":"10115_CR36","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","volume":"374","author":"JJ McMurray","year":"2016","unstructured":"McMurray, J. J., Krum, H., Abraham, W. T., et al. (2016). Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine, 374(16), 1521\u20131532. https:\/\/doi.org\/10.1056\/NEJMoa1514859","journal-title":"New England Journal of Medicine"},{"issue":"7537","key":"10115_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/bmj.332.7537.317","volume":"332","author":"M Coceani","year":"2006","unstructured":"Coceani, M., & Mariotti, R. (2006). Is amiodarone safe in heart failure?. British Medical Journal, 332(7537), 317\u2013318. https:\/\/doi.org\/10.1136\/bmj.332.7537.317","journal-title":"British Medical Journal"},{"key":"10115_CR38","doi-asserted-by":"publisher","first-page":"l476","DOI":"10.1136\/bmj.l476","volume":"364","author":"S Luo","year":"2019","unstructured":"Luo, S., Au Yeung, S. L., Zhao, J. V., et al. (2019). Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: Mendelian randomisation study in UK biobank. Bmj, 364, l476. https:\/\/doi.org\/10.1136\/bmj.l476","journal-title":"Bmj"},{"issue":"7","key":"10115_CR39","doi-asserted-by":"publisher","first-page":"e008755","DOI":"10.1161\/CIRCHEARTFAILURE.121.008755","volume":"15","author":"E Di Lodovico","year":"2022","unstructured":"Di Lodovico, E., Facondo, P., Delbarba, A., et al. (2022). Testosterone, hypogonadism, and heart failure. Circulation: Heart Failure, 15(7), e008755. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008755","journal-title":"Circulation: Heart Failure"},{"issue":"1","key":"10115_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/cts.12883","volume":"14","author":"S Romani","year":"2021","unstructured":"Romani, S., G\u00e9rard, A., Fresse, A., et al. (2021). Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic. Clinical and Translational Science, 14(1), 163\u2013169. https:\/\/doi.org\/10.1111\/cts.12883","journal-title":"Clinical and Translational Science"},{"issue":"1","key":"10115_CR41","doi-asserted-by":"publisher","first-page":"2233425","DOI":"10.1080\/07853890.2023.2233425","volume":"55","author":"J Wang","year":"2023","unstructured":"Wang, J., & Zou, D. (2023). Tirofiban-induced thrombocytopenia. Annals of Medicine, 55(1), 2233425. https:\/\/doi.org\/10.1080\/07853890.2023.2233425","journal-title":"Annals of Medicine"},{"issue":"4","key":"10115_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","volume":"81","author":"SJ Greene","year":"2023","unstructured":"Greene, S. J., Bauersachs, J., Brugts, J. J., et al. (2023). Worsening heart failure: Nomenclature, epidemiology, and future directions: JACC review topic of the week. Journal of the American College of Cardiology, 81(4), 413\u2013424. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.023","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10115_CR43","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J., Packer, M., Desai, A. S., et al. (2014). Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10115_CR44","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg, F. L., & Maurer, M. S. (2024). Cardiac amyloidosis due to transthyretin protein: A review. Journal Of The American Medical Association, 331(9), 778\u2013791. https:\/\/doi.org\/10.1001\/jama.2024.0442","journal-title":"Journal Of The American Medical Association"},{"issue":"20","key":"10115_CR45","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong, P. W., Pieske, B., Anstrom, K. J., et al. (2020). Vericiguat in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 382(20), 1883\u20131893. https:\/\/doi.org\/10.1056\/NEJMoa1915928","journal-title":"New England Journal of Medicine"},{"key":"10115_CR46","doi-asserted-by":"publisher","unstructured":"Wu, S. N., Chen, X. D., Yan, D. (2024). Drug-associated glaucoma: A real-world study based on the Food and Drug Administration adverse event reporting system database. Clinical & Experimental Ophthalmology, https:\/\/doi.org\/10.1111\/ceo.14454","DOI":"10.1111\/ceo.14454"},{"issue":"5","key":"10115_CR47","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/jdv.19703","volume":"38","author":"PM Jedlowski","year":"2024","unstructured":"Jedlowski, P. M., & DuPont, J. P. (2024). Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system. Journal of the European Academy of Dermatology and Venereology, 38(5), 937\u2013944. https:\/\/doi.org\/10.1111\/jdv.19703","journal-title":"Journal of the European Academy of Dermatology and Venereology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10115-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10115-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10115-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:37:01Z","timestamp":1777333021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10115-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10115"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10115-w","relation":{"references":[{"id-type":"doi","id":"10.2165\/00002018-200730070-00011","asserted-by":"subject"}]},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable. Clinical trial number: not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"37"}}